| 1.42 0 (0%) | 09-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.46 | 1-year : | 1.78 |
| Resists | First : | 1.25 | Second : | 1.53 |
| Pivot price | 0.96  |
|||
| Supports | First : | 0.81 | Second : | 0.67 |
| MAs | MA(5) : | 0.95 |
MA(20) : | 1 |
| MA(100) : | 1.99 |
MA(250) : | 4.9 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 18.8 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 21 | Low : | 0.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RENB ] has closed below upper band by 23.6%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.09 |
| Low: | 0.89 - 0.9 | 0.9 - 0.9 |
| Close: | 1.02 - 1.03 | 1.03 - 1.04 |
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Wed, 24 Sep 2025
Lunai Bioworks stock plunges after announcing 10:1 reverse split - Investing.com
Thu, 11 Sep 2025
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - norwichbulletin.com
Tue, 09 Sep 2025
First-Ever AI Safety Platform: Lunai Bioworks Launches Transformer Tech to Secure Drug Discovery & Block Biothreat - Stock Titan
Mon, 08 Sep 2025
AI Drug Discovery Firm Lunai Bioworks Restructures European Business, Maintains Growth Strategy - Stock Titan
Fri, 05 Sep 2025
Lunai Bioworks subsidiary Gedi Cube B.V. files for bankruptcy in Amsterdam - Investing.com
Wed, 27 Aug 2025
AI Biodefense Pioneer Renovaro Transforms into Lunai Bioworks, Expanding Partnerships with Pfizer, Merck - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 36.5 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 122 (K) |
| Shares Short P.Month | 105 (K) |
| EPS | -10.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13.6 % |
| Return on Equity (ttm) | -321.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | -0.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|